BBB Therapeutics B.V.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BBB Therapeutics B.V.
Deal Watch: Leo Pharma Adds Rare Dermatology Disorder Candidate In Timber Buyout
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Dealmaking Quarterly Statistics, Q4 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
Execs On The Move, November 2014
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Life Science Start-Ups: Venture Funding, September 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received VC funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced June through August 2014.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Liposomes
- Other Names / Subsidiaries
-
- to-BBB technologies B.V.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice